IRD insider buying and SEC filings, explained
Opus Genetics, Inc. · CIK 1228627
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$324K
Insiders who bought
1
Sold (not marked 10b5-1)
$19.4M
Planned sales (10b5-1)
$177K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 23, 2026 | Sale | Joseph K. Schachle (President / COO) sold 4,767 shares at $3.57 ($17K). Holdings down 2% to 286,673 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 27, 2026, 4:47 PM ET |
| Oct 23, 2026 | Sale | Benjamin R. Yerxa (President / COO and Director) sold 33,189 shares at about $3.54 ($117K). Holdings down 5% to 670,917 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 27, 2026, 4:41 PM ET |
| Oct 23, 2026 | Planned (10b5-1) | Robert E. Gagnon (CFO) sold 14,000 shares at about $3.55 ($50K), marked as a 10b5-1 plan trade. Holdings down 3% to 542,375 shares. | SEC filing Filed Oct 27, 2026, 4:29 PM ET |
| Oct 23, 2026 | Sale | George Magrath (CEO and Director) sold 9,591 shares at $3.59 ($34K). Holdings down <1% to 2,038,894 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 27, 2026, 4:20 PM ET |
| Sep 30, 2026 | Sale | Foundation Fighting Blindness Retinal Degeneration Fund (Chair and Director) sold 556,000 shares at about $4.96 ($2.8M). Holdings down 15% to 3,236,171 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 1 other reporting owner. | SEC filing Filed Oct 2, 2026, 7:47 PM ET |
| Sep 3, 2026 | Planned (10b5-1) | Robert E. Gagnon (CFO) sold 28,000 shares at about $4.54 ($127K), marked as a 10b5-1 plan trade. Holdings down 5% to 556,375 shares. | SEC filing Filed Sep 8, 2026 |
| Jul 23, 2026 | Sale | Benjamin R. Yerxa (President / COO and Director) sold 7,429 shares at $2.97 ($22K). Holdings down 1% to 704,106 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 27, 2026 |
| Jul 23, 2026 | Sale | Joseph K. Schachle (President / COO) sold 4,644 shares at $2.94 ($14K). Holdings down 2% to 291,440 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 27, 2026 |
| Jul 23, 2026 | Sale | George Magrath (CEO and Director) sold 9,475 shares at about $2.95 ($28K). Holdings down 1% to 1,731,869 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 27, 2026 |
| Jul 23, 2026 | Sale | Robert E. Gagnon (CFO) sold 7,783 shares at about $2.95 ($23K). Holdings down 1% to 584,375 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 27, 2026 |
| May 18, 2026 | Sale | Foundation Fighting Blindness Retinal Degeneration Fund (Chair and Director) sold 1,700,000 shares at $4.35 ($7.4M). Holdings down 31% to 3,792,171 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 1 other reporting owner. | SEC filing Filed May 20, 2026 |
| Apr 23, 2026 | Sale | Benjamin R. Yerxa (President / COO and Director) sold 7,470 shares at about $5.24 ($39K). Holdings down 1% to 711,535 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 27, 2026 |
| Apr 23, 2026 | Sale | Joseph K. Schachle (President / COO) sold 4,697 shares at $5.22 ($25K). Holdings down 2% to 296,084 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 27, 2026 |
| Apr 23, 2026 | Sale | Rabourn Amy Zaremba (Head of Fin. Quality Assurance) sold 1,641 shares at about $5.20 ($9K). Holdings down 1% to 188,671 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 27, 2026 |
| Apr 23, 2026 | Sale | George Magrath (CEO and Director) sold 9,511 shares at $5.22 ($50K). Holdings down 1% to 1,741,344 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 27, 2026 |
| Apr 23, 2026 | Sale | Ashwath Jayagopal (Chief Scientific & Dev. Ofc.) sold 7,542 shares at about $5.19 ($39K). Holdings down 1% to 509,233 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 27, 2026 |
| Apr 23, 2026 | Sale | Robert E. Gagnon (CFO) sold 7,842 shares at about $5.18 ($41K). Holdings down 1% to 592,158 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 27, 2026 |
| Mar 16, 2026 | Sale | Joseph K. Schachle (President / COO) sold 3,719 shares at $5.25 ($20K). Holdings down 1% to 300,781 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 18, 2026 |
| Mar 16, 2026 | Sale | Rabourn Amy Zaremba (Head of Fin. Quality Assurance) sold 2,816 shares at $5.25 ($15K). Holdings down 1% to 190,312 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 18, 2026 |
| Mar 16, 2026 | Sale | George Magrath (CEO and Director) sold 24,438 shares at about $5.21 ($127K). Holdings down 1% to 1,750,855 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 18, 2026 |
| Mar 16, 2026 | Sale | Ashwath Jayagopal (Chief Scientific & Dev. Ofc.) sold 3,719 shares at about $5.12 ($19K). Holdings down 1% to 516,775 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 18, 2026 |
| Dec 29, 2025 | Purchase (code P) | Cam Gallagher (Director) bought 164,000 shares directly and indirectly (by child) at about $1.97 ($324K), reported as a purchase (code P). Direct holdings up 4% to 1,891,430 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 31, 2025 |
| Dec 9, 2025 | Sale | Foundation Fighting Blindness Retinal Degeneration Fund (Chair and Director) sold 4,000,000 shares at $2.15 ($8.6M). Holdings down 42% to 5,492,171 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 1 other reporting owner. | SEC filing Filed Dec 11, 2025 |
25 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow IRD in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.